Northwest Biotherapeutics Inc (QB) (NWBO) News

I think that's why they call it discovery.

MHRA will approve. Your boss just didn’t know when to stop digging nor do you.

I certainly don’t put the odds of NWBO getting the MAA at zero, but more realistically at 5-10%.
But there is possibly a lot of ground to cover by the applicant to even within that margin of probability.

This is just my speculation, which is no different to others here at the other end of the speculative scale, who predict that the SP will be $1000 in 1-2 years after approval .

He is completely clueless.
It was probably a taped message from 12 months ago.

Spoofing Lawsuit question:

If discovery stage is allowed to go forward, may new damage claims be added, based on the findings?

He told me that early January ha ha

Sorry Theorysuit, I meant FeMike not you.

first of all, it is not a fact the NWBO will prevail. That's you desperate hope. despite the gratuitous and self serving pumping there are numerous reasons to be pessimistic about NWBO.

first of all, it is not a fact the NWBO will prevail. That's your desperate hope. despite the gratuitous and self serving pumping there are numerous reasons to be pessimistic about NWBO. But you already know that.

You and Theorysuit are shameless.

Disagree. Lots of pressure applied with the promise of UK Sawston and Advent jobs, as Mr Brown suspects. Plus the various charities and Kings strong arming local politicians. LP and the bunch are no strangers to working the political system. There's a reason they waited all this time to submit until the EMA umbilical cord was cut, IMO.


>>If the MAA is granted, rest assured, it has undergone microscopic scrutiny,

Nature can take a really long time even with breakthrough papers. I have seen it before. Also, NWBOhas nothing to do with the article, it is UCLA and Nature.

Sounds reasonable.

2/3 UCLA

The only responsible parties are UCLA and Nature (plus their reviewers). NWBO is not involved, so skip choice 1, I find it kind of unlikely that the Nature side would be much of a holdup. So that leaves UCLA.

very reasonable that a review cycle could take some time, especially if authors are busy. This is an interim update on an ongoing P2, not exactly earth shaking news (despite what longs here think). I see no reason why all authors would drop what they are doing to respond to a review request code blue.

I also see no reason to sync with some external event. Sometimes papers are timed in conjunction with a conference presentation to avoid pre-disclosure. But with the pre-print already disclosed that looks unlikely (though I guess a possibility).

I previously thought it possible that UCLA would skip this if the final data was soon. But with the trial still ongoing, and looking like they might be still trying to reopen enrollment, the paper on the primary analysis could be years away.

You mean When of course not if.

When the MAA is granted, rest assured, it has undergone microscopic scrutiny, and then NWBO will certainly have something to crow about !

It is the first time in over 30 years an advancement in rGBM has been achieved in a clinical trial. MHRA will approve. Your boss just didn’t know when to stop digging nor do you.

Completely agree
After more than a decade … it’s “ show me the money time” . Promise time is long gone .

Here's hoping it does, right?

5. And when you say them, you don't want to upstage or put pressure on the MHRA.

I certainly feel that it is the case that the MHRA are under enough pressure, as it is, with this DCVax-L MAA application, and establishing it efficacy !

Which, of course, is the role of an independent, unbiased Regulator.

If the MAA is granted, rest assured, it has undergone microscopic scrutiny, and then NWBO will certainly have something to crow about !

Nothing else matters at this point except large non dilutive funding from big pharma in the coming months. Without that, even UK approval wouldn't bring the ($3-5B) market cap valuation we deserve and shorts will continue to slam the stock on any upside we get at UK approval. If LP can not bring big pharma in Q3/Q4 then I’d personally move on from this investment.

Whats even more funny is, that Linda Powers with lots of experience in biotech matters and BP, predicted the possibility of manipulation, fraud and corruption long time ago, if setting up operations on US soil, which every non fraudulent retailer now only can rejoice she had that clearsight and have had a tight cooperation with MHRA and now have a tight grip round Market Makers balls.

I know it hurts like hell, that you guys have to work overtime with only bullshit narratives at your disposal, but don't fret to much.

It'll soon be over and you can find another stock and another pay cheque from the criminal cabal.

Good luck soon hitting 700.000 posts in this shit OTC stock 👍🏻

I've only owned AVXL a few months, but I've never seen a stock where more posters want to fire the CEO. The one news item that crops up weekly, sometimes almost every day when you hit the headline link here is, the Gross Law firm gathering stock owners for a class action suit. I really don't know how they do it, you can cure cancer and get a headline for a day, keep announcing you're suing the company and it shows all the time. Anyway my point is that companies and their CEO's get flak all the time while they don't have an approved product for sale. On approval these very same people will be toasted for their brilliance.

AVXL's market cap is much smaller than NWBO, but market cap doesn't put you on a major stock exchange, stock price does and while it's down some on recent news, it's well above the minimum for maintaining an Nasdaq listing. Like NWBO they're in peer review for a Journal article, and it seems to be taking forever. I frankly forget how many months our initial Journal article took, or just how many months Nature has been working on the next one.

My point is only that all companies where products are slow to approval get criticism and frankly it's progress that limits it, then approval, without that CEO's get raked over the coals regardless of whether they issue PR's, have quarterly webcasts, etc. LP probably gets less flak from us than Missling, AVXL's CEO, does, and he does quarterly conference calls, etc. I believe that both companies will be successful in time. I like NWBO's potential more, but if AVXL can play a roll in Alzheimer's, Parkinson's, RETT's, etc it too could be huge. I believe NWBO's success will come first, but in time AVXL's success will come, and it won't matter if they replace the CEO or not.

Gary

5 Approval.
Best advertisement in town!

Trading at 3 year lows on SP. Volume not so.

So FOS. You “held” conference calls, ok Gronk

That’s a quarterly CC that no one gets any value from, if you’re a serious investor.
10Q’s are perfect for now.
But….i noticed you said you “held” quarterly conference calls. Now that be some serious entertainment- you do a good Gronk I betcha.

Do you recall ever seeing a hit piece and MM working together to crush landmark top line trial results for Cancer?

When did I dispute that
I was commenting g on time it takes to publish something

Abstract
Nature, Science, and PNAS are the three most prestigious general-science journals, and Nature and
Science are among the most influential journals overall, based on the journal Impact Factor (IF).


https://arxiv.org/pdf/2008.04721#:~:text=Nature%2C%20Science%2C%20and%20PNAS%20are,journal%20Impact%20Factor%20(IF).

ADAP does gets collab revenue, but they don't technically sell any products.

I'm not a fan at all of what NWBO does in terms of communication.

What's even more funny is UK based companies with manufacturing facilities in the UK seek approval with FDA first. That's what smart companies that actually plan on making revenue actually do.

ADAP - $60 million in revenue last year; not pre-revenue

GERN - $400 million in cash

Yes, I would expect those companies to be more likely to have calls.

You say this is normal behavior, but only i need provide proof? Promise you are going to have to dig hard to find one that doesn't PR quarterly results and/or doesn't hold a quarterly call.

Why don't you show me one that doesn't do a quarterly PR and quarterly call?

And IOVA was approved at the end of Feb, so don't pull down any revenues yet. The current quarter is their first quarter of actually pulling revenue, so technically it is still pre-revenue until this Q.

Here's another example for you.

I also own ADAP in addition to IOVA. UK based microcap with a much smaller cap than NWBO. Sorry guys but cell therapy is here and ready to commercialize while NWBO spins their wheels.

https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/256/adaptimmune-reports-third-quarter-financial-results-and

GERN as a bonus (don't own it though)
https://ir.geron.com/investors/press-releases/press-release-details/2024/Geron-Corporation-Reports-Business-Highlights-and-Fourth-Quarter-and-Full-Year-2023-Financial-Results/default.aspx

I ask for a prerev biotech and you give me one with multiple approved drugs and a 4 billion dollar market cap.

Okay, very comparable.

Let's be amicable and I'll give you that as one example.

Please provide another. You claim that in your long experience of investing in prerev biotechs you've never seen one that doesn't do quarterly calls. So you should be able to pretty quickly rattle me off a list of 5 or 6 tickers that I can research for myself. I assume your vast experience in this area means you've got 5 or 6 tickers for me.

They also usually have put out quarterly PRs on the current state of financials, progress and upcoming milestones with projected timelines.


https://ir.iovance.com/news-releases/news-release-details/iovance-biotherapeutics-reports-fourth-quarter-and-full-year-5

https://ir.iovance.com/news-releases/news-release-details/iovance-biotherapeutics-reports-second-quarter-and-first-half-1

Check out this guidance: has clear timelines of what is upcoming, and nice summary of what occurred. This is what NWBO doesn't do. I own this one so i follow closely.

Where does NWBO put out any timelines? Where are you in the Approval process and where is the guidance? I'm going to give you 2025 approval decision or beyond based on Vertex last approval. And i said PR not 10Q. By law you need a 10Q, but there is no law that says you need a quarterly PR. But it is nice to have.

They also usually have put out quarterly PRs on the current state of financials, progress and upcoming milestones with projected timelines.

That's pretty much the standard across the ones i've seen or held. So this no Qtrly call or qtry guidance is most definitely not normal to me.

Also, NWBO publishes all of this information, every quarter, just like you ask. That you don’t know what a 10Q is, is not my problem.

Give me some examples of the ones you do recall please thanks

Give me a few examples please

Actually, they have told this myth for 10 years now for about the 10th time.

Thanks - Don't know how I missed that, I'm been here for almost 10 years maybe more who the heck knows. And for the last 15 months every day.
Every minute well almost.

Even added today and will again.

I will pass on the entire press release to the family.

Thanks

Gus, does this help?

https://nwbio.com/northwest-biotherapeutics-announces-approval-of-pediatric-investigation-plan-pip-by-mhra-pip-approval-is-a-pre-requisite-for-application-for-approval-of-a-new-medicine-for-adult-patients/

Regarding (ATL-DC + poly-ICLC trial): why it's not indicated on their website? Only DCVax® – L, DCVax® – Direct, and DCVax® – Prostate are listed there.

the pumpers here love to throw out this prerevenue word and describe whatever NWBO does as the norm.

what they state as normal is definitely not what other companies do.

I understand if a UK based company that has mfg facility in the UK, aka Adaptimmune. But a US based bio with a UK Mfg (and this mfg owned by the CEO's Fund). That is most definitely not normal And a double red flag to boot.

Pre-Revenue…

Ie.. https://investorshub.advfn.com/uimage/uploads/2024/5/7/xi%5Bed6ECDD2C7-C8EF-4684-A2A2-B9315F74A577.jpeg

For the most part, most of the pre-rev bios do hold calls and also put out a PR with the Qtrly results where they kind of summarize what goes on in the call. In summary, most prerevenue bios do both a call and PR that summarizes the info of the call. That is definitely the norm. Don't let these pumpers tell you any differently.

It is not unusual at all for prerevenue companies, especially in the biotech space, to not have quarterly conference calls.

I don't know which prerevenue biotechs you hold or have held, but all the ones i follow or ever held have most definitely have held quarterly calls with:
1. Financial expenditures, cash position
2. Highlights of the current progress in the Qtr
3. Highlights of upcoming milestones.

They also usually have put out quarterly PRs on the current state of financials, progress and upcoming milestones with projected timelines.

That's pretty much the standard across the ones i've seen or held. So this no Qtrly call or qtry guidance is most definitely not normal to me.

Well if you ask this question here you will be labeled paid basher. Be careful

You have got to stop calling this one a "Pre revenue". That infers it's a normal biotech. For ten years various people have been calling for revenue coming in every year. It never happens! Joan said $100M was supposed to happen two years ago. LP doesn't do cc's because she doesn't want to get caught having to explain anything. Instead you people here do it for her. It's a joke.

The pre revenue companies I have held may not have calls but do have at least pit out a pr - no call can be due to no analysts covering. The pr was usually an update and trying to show investors what they have to hopefully get some buying of the stock. Here communication is limited. We have a company with a (imo) solid product submitted for approval and little communication and trading near 3 year lows
I have had several pre-revenue companies that did much more communication

That's total BS! I can't recall any active Pll/lll that didn't hold quarterly calls, let alone a U.S. one claiming great success and with a manufacturing facility in the UK. What a joke.

$nwbo @alphavestcap @brianegolf2 @metacollectiveG @ATLnsider @SmithOnStocks1 @glen_bwrhr42 @hoffmann6383 @TiltMyBrain @ATLnsider @hoffman6383 : (https://t.co/QmMgTTRoRN)

"NWBO was granted a deferral on the PIP. At minimum this means the initiation of the trial was deferred…— alphavestcapital.com (@alphavestcap) May 7, 2024